

Quoc-Dien Trinh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9028125/publications.pdf>

Version: 2024-02-01

653
papers

19,565
citations

12330

69
h-index

30922

102
g-index

661
all docs

661
docs citations

661
times ranked

16378
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer and Prostatic Diseases, 2023, 26, 287-292.	3.9	3
2	Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase. Journal of the American Academy of Dermatology, 2023, 88, 179-181.	1.2	8
3	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	4.2	6
4	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e1-62.e11.	1.6	1
5	Analysis of Surgical Volume in Military Medical Treatment Facilities and Clinical Combat Readiness of US Military Surgeons. JAMA Surgery, 2022, 157, 43.	4.3	33
6	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. JCO Oncology Practice, 2022, 18, e204-e218.	2.9	18
7	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12
8	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	2.5	2
9	Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. European Urology, 2022, 81, 323-324.	1.9	4
10	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
11	Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. JAMA Network Open, 2022, 5, e225740.	5.9	15
12	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 29	1.0	0
13	Digital technologies in cancer care: a review from the clinician's perspective. Journal of Comparative Effectiveness Research, 2022, , .	1.4	8
14	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors and androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	4
15	Hormone Treatment of Prostate Cancer:. Urologic Clinics of North America, 2022, 49, 309-321.	1.8	1
16	Association Between Alcohol Intake and Prostate Specific Antigen Screening: Results from a National Behavioral Survey. Urology, 2022, , .	1.0	0
17	Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades. European Urology Oncology, 2021, 4, 834-836.	5.4	5
18	Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals. Journal of Gastrointestinal Surgery, 2021, 25, 1847-1856.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Real-world comparative effectiveness of shockwave lithotripsy versus ureterorenoscopy for the treatment of urinary stones. <i>World Journal of Urology</i> , 2021, 39, 2177-2182.	2.2	1
20	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1644-1650.	2.4	2
21	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 719-726.	6.3	45
22	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. <i>Cancer</i> , 2021, 127, 249-256.	4.1	19
23	Access denied: The relationship between patient insurance status and access to high-volume hospitals. <i>Cancer</i> , 2021, 127, 577-585.	4.1	26
24	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 79, 595-604.	1.9	111
25	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. <i>JAMA Dermatology</i> , 2021, 157, 35.	4.1	57
26	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394.	4.1	10
27	The Relationship Between Health Literacy and Nonrecommended Cancer Screening. <i>American Journal of Preventive Medicine</i> , 2021, 60, e69-e72.	3.0	6
28	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. <i>Urology</i> , 2021, 147, 199-204.	1.0	9
29	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2021, 4, 66-72.	5.4	20
30	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	3.1	31
31	Where Is the Value in Ambulatory Versus Inpatient Surgery?. <i>Annals of Surgery</i> , 2021, 273, 909-916.	4.2	51
32	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. <i>Lung</i> , 2021, 199, 199-211.	3.3	7
33	Temporal trends in the incidence of distant-stage bladder cancer among young individuals. <i>International Journal of Urology</i> , 2021, 28, 704-705.	1.0	2
34	A New Era in Surgical Evaluation—What Is at Stake?. <i>JAMA Surgery</i> , 2021, 156, e206360.	4.3	0
35	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2021, 7, 458.	7.1	177
36	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. <i>American Journal of Surgery</i> , 2021, 222, 998-1004.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. <i>Cancer</i> , 2021, 127, 2525-2534.	4.1	3
38	Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. <i>BJU International</i> , 2021, , .	2.5	1
39	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study. <i>Bladder Cancer</i> , 2021, 7, 173-185.	0.4	0
40	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. <i>Cancer</i> , 2021, 127, 2714-2723.	4.1	12
41	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. <i>Journal of Urology</i> , 2021, 205, 1263-1274.	0.4	10
42	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e654-e665.	2.9	11
43	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. <i>Eur Urol</i> 2021;79:605–6. <i>European Urology</i> , 2021, 79, 607-608.	1.9	0
44	Value-Based Healthcare in Urology: A Collaborative Review. <i>European Urology</i> , 2021, 79, 571-585.	1.9	27
45	Cardiovascular toxicities associated with abiraterone compared to enzalutamide –A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021, 36, 100887.	7.1	16
46	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 733-741.	1.4	4
47	Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use –Reply. <i>JAMA Dermatology</i> , 2021, 157, 738.	4.1	2
48	Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsi –Ms Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>Eur Urol</i> 2021;79:595–604. Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performin. <i>European Urology</i> , 2021, 79, e184-e185.	1.9	0
49	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 413-418.	1.3	8
50	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. <i>Journal of Urology</i> , 2021, 205, 1605-1611.	0.4	11
51	Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. <i>Annals of Surgical Oncology</i> , 2021, 28, 8688-8696.	1.5	25
52	ASO Author Reflections: How We Convey Empathy, Address Uncertainty, and Share Serious News: Challenges to Remote Surgical Care. <i>Annals of Surgical Oncology</i> , 2021, 28, 8697-8698.	1.5	0
53	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	2.2	3
54	Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e9-790.e15.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 1467.	7.1	14
56	Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e1-791.e7.	1.6	5
57	Is the current referral trend a threat to the Military Health System? Perioperative outcomes and costs after colorectal surgery in the Military Health System versus civilian facilities. Surgery, 2021, 170, 67-74.	1.9	7
58	Association of the hospital readmission reduction program with readmission and mortality outcomes after coronary artery bypass graft surgery. Journal of Cardiac Surgery, 2021, 36, 3251-3258.	0.7	1
59	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	1.6	4
60	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1042-1044.	16.8	23
61	Research highlights of the 2020 society of urologic oncology young urologic oncologists™ program. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 452-454.	1.6	0
62	Predicting survival after radical prostatectomy: Variation of machine learning performance by race. Prostate, 2021, 81, 1355-1364.	2.3	2
63	Limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population level. Journal of the American Academy of Dermatology, 2021, 85, e195-e196.	1.2	2
64	Measuring What Matters: Patient-Reported Outcome and Experience Measures for Men Undergoing Radical Prostatectomy. European Urology Focus, 2021, 7, 913-915.	3.1	8
65	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. European Urology Open Science, 2021, 33, 1-10.	0.4	7
66	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investigative and Clinical Urology, 2021, 62, 56.	2.0	4
67	Trends in Surgical Volume in the Military Health System—A Potential Threat to Mission Readiness. Military Medicine, 2021, 186, 646-650.	0.8	24
68	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	3.1	8
69	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. European Urology Focus, 2020, 6, 74-80.	3.1	8
70	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	3.9	39
71	Pathologic measures of quality compare favorably in patients undergoing robot-assisted radical cystectomy to open cystectomy cohorts: a National Cancer Database analysis. Journal of Robotic Surgery, 2020, 14, 609-614.	1.8	3
72	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Suicide Risk Among Patients with Genitourinary Malignancies: Where Do We Stand?. European Urology Focus, 2020, 6, 1145-1146.	3.1	2
74	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European Urology Oncology, 2020, 3, 104-111.	5.4	11
75	Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group's American College of Radiology Imaging Network E2805 Trial Cohort. European Urology, 2020, 77, 277-281.	1.9	18
76	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology, 2020, 135, 44-49.	1.0	5
77	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. Cancer, 2020, 126, 496-505.	4.1	19
78	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. Journal of Surgical Oncology, 2020, 121, 578-583.	1.7	6
79	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 163-167.	1.3	19
80	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 74.e13-74.e20.	1.6	6
81	Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e7-78.e13.	1.6	7
82	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Annals of Surgical Oncology, 2020, 27, 1929-1936.	1.5	3
83	Care Setting as a Modifiable Predictor of Perioperative Cost and Outcomes following Elective Urinary Stone Surgery. Urology Practice, 2020, 7, 259-265.	0.5	3
84	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World Journal of Urology, 2020, 38, 2227-2236.	2.2	12
85	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	3.9	17
86	Clinical applications of artificial intelligence in urologic oncology. Current Opinion in Urology, 2020, 30, 748-753.	1.8	4
87	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Current Opinion in Urology, 2020, Publish Ahead of Print, 701-710.	1.8	6
88	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surgery, 2020, 20, 235.	1.3	2
89	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	1.6	2
90	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology, 2020, 145, 197-203.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	5.9	37
92	Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer and Prostatic Diseases, 2020, 23, 564-566.	3.9	2
93	Accounting for Readinessâ€”Integrating Time-Driven Activity-Based Costing (TDABC) into the Military Health System. Military Medicine, 2020, 185, e930-e933.	0.8	5
94	Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296.	1.0	1
95	Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Procedures. Journal of Endourology, 2020, 34, 1248-1254.	2.1	12
96	Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 582-589.	1.6	6
97	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. American Journal of Surgery, 2020, 220, 441-447.	1.8	7
98	All for one, one for all: is centralisation the way to go?. BJU International, 2020, 125, 191-192.	2.5	2
99	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Network Open, 2020, 3, e1919185.	5.9	18
100	Prostate cancer and kidney transplantation â€” exclusion or coexistence?. BJU International, 2020, 125, 628-629.	2.5	5
101	Lower odds of cardiac events for gonadotrophinâ€”releasing hormone antagonists versus agonists. BJU International, 2020, 126, 9-10.	2.5	11
102	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Nonâ€”muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	1.9	7
103	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	5.9	87
104	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.4	61
105	Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy. Journal of Urology, 2020, 204, 564-569.	0.4	3
106	Association of abiraterone and higher odds of cardiac complications compared to enzalutamide.. Journal of Clinical Oncology, 2020, 38, 70-70.	1.6	6
107	Response to Loughlin re: â€”Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Surgeryâ€”by Nguyen et al.. Journal of Endourology, 2020, 34, 1256-1257.	2.1	0
108	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR MHealth and UHealth, 2020, 8, e20224.	3.7	14
110	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	1.9	11
111	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
112	EDITORIAL COMMENT. Urology, 2019, 130, 84-85.	1.0	0
113	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
114	Machines in urology: a brief odyssey of the future. BJU International, 2019, 124, 545-546.	2.5	1
115	Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-555. Comparing Apples to Oranges: A Self-fulfilling Prophecy?. European Urology, 2019, 75, e125-e126.	1.9	0
116	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?. BJU International, 2019, 123, 197-198.	2.5	2
117	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	1.9	11
118	Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	5.9	60
119	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	2.2	4
120	Trimodal Therapy for Bladder Cancer. JAMA Surgery, 2019, 154, e191637.	4.3	0
121	Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-555. European Urology, 2019, 76, e76-e77.	1.9	0
122	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	5.9	23
123	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. New England Journal of Medicine, 2019, 380, 2070-2072.	27.0	42
124	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	1.6	5
125	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	3.9	8
126	Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology, 2019, 37, 2737-2746.	2.2	6

#	ARTICLE	IF	CITATIONS
127	Treatment delays for muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 1973-1975.	4.1	4
128	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019, 37, 923-931.	1.6	78
129	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , 2019, 2, 349-354.	5.4	6
130	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 265-273.	5.4	75
131	Trends in Regionalization of Care and Mortality For Patients Treated With Radical Cystectomy. <i>Medical Care</i> , 2019, 57, 728-733.	2.4	10
132	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	1.9	43
133	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 125-136.	3.9	53
134	Effect of Medicaid Expansion on Colorectal Cancer Screening Rates. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 97-103.	1.3	48
135	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019, 26, 297-305.	1.5	20
136	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065.	2.2	40
137	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. <i>European Urology</i> , 2019, 75, 352-353.	1.9	32
138	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 552-555.	1.9	43
139	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	4.1	56
140	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	4.1	20
141	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
142	Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. <i>BJU International</i> , 2019, 123, 385-387.	2.5	6
143	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46.	2.5	17
144	Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy. <i>Urology</i> , 2019, 123, 174-180.	1.0	17

#	ARTICLE	IF	CITATIONS
145	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019, 5, 474-481.	3.1	44
146	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. <i>European Urology Focus</i> , 2019, 5, 77-80.	3.1	43
147	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.4	31
148	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. <i>Urology Practice</i> , 2019, 6, 159-164.	0.5	3
149	MP41-09 QUALITY OF CARE IN THE TREATMENT OF LOCALIZED INTERMEDIATE AND HIGH RISK PROSTATE CANCER AT MINORITY SERVING HOSPITALS. <i>Journal of Urology</i> , 2019, 201, .	0.4	1
150	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , 2019, 201, 728-734.	0.4	4
151	Providers' inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2019, 37, 77-77.	1.6	1
152	Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men.. <i>Journal of Clinical Oncology</i> , 2019, 37, 84-84.	1.6	2
153	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1049-1058.	4.9	21
154	Radical prostatectomy for high-risk prostate cancer Opinion: YES. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 424-427.	1.5	1
155	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2018, 10, 3-10.	2.0	3
156	Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. <i>JAMA Oncology</i> , 2018, 4, 643.	7.1	54
157	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 573-581.	0.4	31
158	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17.	1.6	21
159	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. <i>Lancet Oncology</i> , The, 2018, 19, e66.	10.7	2
160	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70.. <i>European Urology</i> , 2018, 73, e96-e97.	1.9	0
161	Reassessing the value of high-volume cancer care in the era of precision medicine. <i>Cancer</i> , 2018, 124, 1319-1321.	4.1	20
162	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1417-1425.	0.4	70

#	ARTICLE	IF	CITATIONS
163	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	2.5	27
164	The new frontier of prostate biopsy: determining the role of imageâ€¢guidance in moving the needle. BJU International, 2018, 121, 4-5.	2.5	0
165	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases, 2018, 21, 364-372.	3.9	48
166	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	1.6	52
167	Editorial Comment. Journal of Urology, 2018, 199, 914-914.	0.4	0
168	Differences in Survival Associated with Performance of Lymph Node Dissection inÂ¢Patients with Invasive Penile Cancer: Results from the National Cancer Database. Journal of Urology, 2018, 199, 1238-1244.	0.4	24
169	Factors Influencing Prostate Specific Antigen Testing in the United States. Urology Practice, 2018, 5, 438-443.	0.5	1
170	Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard. Cancer, 2018, 124, 1299-1300.	4.1	0
171	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	3.1	15
172	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Nodeâ€¢Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€¢Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18
173	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. European Urology Focus, 2018, 4, 568-571.	3.1	6
174	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. European Urology Focus, 2018, 4, 1002-1004.	3.1	4
175	Systematic Review of the Volumeâ€¢Outcome Relationship for Radical Prostatectomy. European Urology Focus, 2018, 4, 775-789.	3.1	68
176	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	1.9	20
177	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. JAMA Oncology, 2018, 4, 128.	7.1	20
178	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	2.5	30
179	External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. Journal of Urology, 2018, 199, 649-654.	0.4	17
180	Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 116-121.	1.8	11

#	ARTICLE	IF	CITATIONS
181	Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer. <i>BJU International</i> , 2018, 121, 345-347.	2.5	9
182	Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 193-212.	1.6	1
183	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139.	1.9	17
184	Secondary data sources for health services research in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 165-173.	1.6	48
185	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , 2018, 73, 452-461.	1.9	46
186	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018, 124, 55-64.	4.1	40
187	The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018, 199, 424-429.	0.4	33
188	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. <i>Urology Practice</i> , 2018, 5, 377-382.	0.5	1
189	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 78.e13-78.e19.	1.6	16
190	Understanding the impact and challenges of secondary data analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 163-164.	1.6	10
191	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. <i>Urology</i> , 2018, 112, 56-65.	1.0	7
192	Reply to Aditya Bagrodia, Solomon Wolodu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e100-e101.	1.9	1
193	Prostate Cancer Screening in Early Medicaid Expansion States. <i>Journal of Urology</i> , 2018, 199, 81-88.	0.4	28
194	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018, 73, 445-451.	1.9	43
195	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	1.9	62
196	What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?. <i>Translational Andrology and Urology</i> , 2018, 7, 732-735.	1.4	3
197	Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. <i>Kidney Cancer</i> , 2018, 2, 47-55.	0.4	1
198	Challenges facing regionalization of radical cystectomy. <i>Translational Andrology and Urology</i> , 2018, 7, 292-294.	1.4	2

#	ARTICLE	IF	CITATIONS
199	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1619.	7.1	0
200	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	1.6	1
201	Health Services Research and Robotic Surgery. , 2018, , 235-252.		0
202	Use of Preventive Health Services Among Cancer Survivors in the U.S.. American Journal of Preventive Medicine, 2018, 55, 830-838.	3.0	11
203	Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care. Current Urology Reports, 2018, 19, 100.	2.2	3
204	Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib renal masses: An analysis of the national cancer data base. Cancer, 2018, 124, 3839-3848.	4.1	37
205	Melancholia and cancer: The bladder cancer narrative. Cancer, 2018, 124, 3080-3083.	4.1	2
206	Contemporary trends in the utilisation of radical prostatectomy. BJU International, 2018, 122, 726-728.	2.5	7
207	Costs variations for percutaneous nephrolithotomy in the U.S. from 2003 to 2015: A contemporary analysis of an all-payer discharge database. Canadian Urological Association Journal, 2018, 12, .	0.6	6
208	Bladder Extirpation vs Preservation. JAMA Surgery, 2018, 153, 889.	4.3	1
209	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.6	2
210	Does the Surgical Apgar Score predict serious complications after elective major cancer surgery?. Journal of Surgical Research, 2018, 231, 242-247.	1.6	4
211	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	1.6	37
212	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	2.2	12
213	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. European Journal of Surgical Oncology, 2018, 44, 1439-1445.	1.0	32
214	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. European Urology, 2018, 74, 387-393.	1.9	41
215	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	5.4	59
216	Shared decision making for prostate cancer screening: Reality or farce?. Journal of Clinical Oncology, 2018, 36, 107-107.	1.6	3

#	ARTICLE	IF	CITATIONS
217	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 78-78.	1.6	0
218	Do accountable care organizations impact prostate cancer screening?. Journal of Clinical Oncology, 2018, 36, 6546-6546.	1.6	0
219	Editorial Comment. Journal of Urology, 2018, 200, 987-988.	0.4	0
220	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. European Urology, 2017, 72, 14-19.	1.9	128
221	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. Urology Practice, 2017, 4, 388-394.	0.5	2
222	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	1.9	7
223	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. Urology Practice, 2017, 4, 210-217.	0.5	1
224	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	1.6	104
225	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Current Urology Reports, 2017, 18, 15.	2.2	49
226	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	1.0	27
227	Could lead-time bias explain the apparent benefits of early salvage radiotherapy?. Nature Reviews Urology, 2017, 14, 193-194.	3.8	11
228	Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e9-460.e20.	1.6	22
229	Challenging Residual Contamination of Instruments for Robotic Surgery in Japan. Infection Control and Hospital Epidemiology, 2017, 38, 501-502.	1.8	2
230	Risk Assessment in Small Renal Masses. Urologic Clinics of North America, 2017, 44, 189-202.	1.8	6
231	Do micropapillary patients benefit from chemotherapy?. BJU International, 2017, 119, 656-658.	2.5	5
232	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	1.9	110
233	Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer, 2017, 123, 3241-3252.	4.1	89
234	Weighing the evidence from surgical trials. BJU International, 2017, 119, 659-660.	2.5	10

#	ARTICLE	IF	CITATIONS
235	National treatment trends among older patients with T1-localized renal cell carcinoma11Dr. Simon P. Kim is supported by a career development award from the Conquer Cancer Foundation from the American Society of Clinical Oncology.. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e15-113.e21.	1.6	24
236	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	1.9	40
237	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Medical Care, 2017, 55, 398-404.	2.4	36
238	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	1.6	6
239	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.4	31
240	Secondary data analysis. Current Opinion in Urology, 2017, 27, 354-359.	1.8	44
241	Accountable care organizations and the use of cancer screening. Preventive Medicine, 2017, 101, 15-17.	3.4	18
242	Complications After Metastasectomy for Renal Cell Carcinomaâ€”A Population-based Assessment. European Urology, 2017, 72, 171-174.	1.9	44
243	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.8	9
244	Emerging guidelines for managing small renal masses. Nature Reviews Urology, 2017, 14, 329-330.	3.8	1
245	Active Surveillance for the Small Renal Mass. Urologic Clinics of North America, 2017, 44, 213-222.	1.8	15
246	The Small Renal Mass and Its Management in Urologic Practice. Urologic Clinics of North America, 2017, 44, xvii.	1.8	2
247	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	13.7	5
248	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. European Urology, 2017, 72, 64-75.	1.9	91
249	The Effect of Physician Specialty Obtaining Access for Percutaneous Nephrolithotomy on Perioperative Costs and Outcomes. Journal of Endourology, 2017, 31, 1152-1156.	2.1	14
250	Race and postoperative complications following urologic cancer surgery: An ACS-NSQIP analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e1-670.e6.	1.6	8
251	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 665-669.	1.6	0
252	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.4	10

#	ARTICLE	IF	CITATIONS
253	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladderâ€ preservation therapy for muscleâ€ invasive bladder cancer. Cancer, 2017, 123, 4337-4345.	4.1	72
254	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€ invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	4.1	138
255	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. Clinical Genitourinary Cancer, 2017, 15, e955-e968.	1.9	17
256	National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. Cancer Treatment and Research Communications, 2017, 12, 14-18.	1.7	0
257	PD05-11 CONTEMPORARY PERCEPTIONS OF HUMAN PAPILLOMAVIRUS AND PENILE CANCER â€ PERSPECTIVES FROM A NATIONAL SURVEY. Journal of Urology, 2017, 197, .	0.4	0
258	PD32-05 PROSTATE CANCER SCREENING: EFFECT OF EARLY MEDICAID EXPANSION. Journal of Urology, 2017, 197, .	0.4	2
259	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. International Journal of Urology, 2017, 24, 743-748.	1.0	34
260	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.8	6
261	Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e17-662.e21.	1.6	13
262	Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e15-670.e21.	1.6	16
263	Immortalâ€ time bias: a crucial yet overlooked confounder in urological research. BJU International, 2017, 120, 455-455.	2.5	1
264	Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488â€9. European Urology, 2017, 72, 489-491.	1.9	1
265	Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008â€2012). Journal of Endourology, 2017, 31, 91-99.	2.1	15
266	Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clinical Genitourinary Cancer, 2017, 15, 326-335.e3.	1.9	43
267	Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. Journal of Urology, 2017, 197, 31-36.	0.4	14
268	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	1.9	18
269	Does Low-value Care Affect Urologists?. European Urology, 2017, 71, 304-305.	1.9	2
270	Postoperative sepsis prediction in patients undergoing major cancer surgery. Journal of Surgical Research, 2017, 209, 60-69.	1.6	15

#	ARTICLE	IF	CITATIONS
271	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403â€“6. European Urology, 2017, 71, e47-e48.	1.9	3
272	Reply to C. Buttiglierio et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	1.6	0
273	Minimally invasive vs open nephrectomy in the modern era: does approach matter?. World Journal of Urology, 2017, 35, 1557-1568.	2.2	36
274	Pneumonia after Major Cancer Surgery: Temporal Trends and Patterns of Care. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	12
275	Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kiloâ€Joules per gram of prostate?. BJU International, 2016, 118, 633-640.	2.5	28
276	Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in boys: a populationâ€based study 1998â€“2010. BJU International, 2016, 118, 969-979.	2.5	7
277	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	2.5	14
278	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	2.5	39
279	Association of Androgen Deprivation Therapy With Alzheimerâ€™s Disease: Unmeasured Confounders. Journal of Clinical Oncology, 2016, 34, 2801-2803.	1.6	6
280	Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology, 2016, 95, 88-94.	1.0	29
281	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	2.5	22
282	Data on Medicare eligibility and cancer screening utilization. Data in Brief, 2016, 7, 679-681.	1.0	4
283	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	3.1	7
284	MP37-02 INFORMED DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING. Journal of Urology, 2016, 195, .	0.4	0
285	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	1.6	34
286	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony Dâ€™Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756â€“65. European Urology, 2016, 69, e129.	1.9	0
287	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. Urology, 2016, 90, 69-75.	1.0	18
288	Editorial Comment. Journal of Urology, 2016, 196, 333-334.	0.4	0

#	ARTICLE	IF	CITATIONS
289	MP21-07 THE AFFORDABLE CARE ACT AND PSA SCREENING PRACTICES: ANALYSIS OF RACIAL SUBGROUPS. Journal of Urology, 2016, 195, .	0.4	0
290	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	1.0	10
291	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	1.6	121
292	Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406.	1.9	80
293	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	1.6	43
294	Editorial Comment. Urology, 2016, 95, 101-102.	1.0	0
295	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	1.8	33
296	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	2.8	32
297	The diminishing returns of robotic diffusion: complications after robotâ€assisted radical prostatectomy. BJU International, 2016, 117, 211-212.	2.5	4
298	Wound dehiscence in a sample of 1Â776 cystectomies: identification of predictors and implications for outcomes. BJU International, 2016, 117, E95-E101.	2.5	23
299	Accurately determining patients who underwent robotâ€assisted surgery: limitations of administrative databases. BJU International, 2016, 118, 346-348.	2.5	10
300	Relationship between androgen deprivation therapy and communityâ€acquired respiratory infections in patients with prostate cancer. International Journal of Urology, 2016, 23, 305-311.	1.0	10
301	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.5	13
302	Risk of Small Bowel Obstruction After Robot-Assisted <i>vs</i> Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	2.1	4
303	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	4.1	27
304	Menâ€™s health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. American Journal of Clinical Nutrition, 2016, 104, 1583-1593.	4.7	2
305	Active Surveillance for Small Renal Masses: When Less is More. European Urology Focus, 2016, 2, 660-668.	3.1	31
306	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	4.9	10

#	ARTICLE	IF	CITATIONS
307	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoablative Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	1.6	185
308	Observational Studies to Contextualize Surgical Trials. European Urology, 2016, 70, 231-232.	1.9	2
309	MP25-08 DETERMINANTS OF PROSTATE CANCER SCREENING IN ASIAN AMERICANS. Journal of Urology, 2016, 195, .	0.4	0
310	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive Medicine, 2016, 89, 140-145.	3.4	63
311	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2016, 69, 963-964.	1.9	2
312	MP39-14 IMPACT OF THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PROSTATE SPECIFIC ANTIGEN SCREENING ON PROSTATE CANCER RISK GROUP STRATIFICATION. Journal of Urology, 2016, 195, .	0.4	3
313	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.4	42
314	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	1.6	70
315	Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology, 2016, 96, 54-61.	1.0	16
316	New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (<sc>COX</sc>) blockers in erectile dysfunction. BJU International, 2016, 117, 385-386.	2.5	2
317	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	1.9	72
318	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	7.1	5
319	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	1.6	17
320	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.4	32
321	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 837-845.	1.9	178
322	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. JAMA Internal Medicine, 2016, 176, 546.	5.1	32
323	Adverse Event Rates, Timing of Complications, and the Impact of Specialty on Outcomes Following Adrenal Surgery: An Analysis of 30-Day Outcome Data From the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Urology, 2016, 90, 62-68.	1.0	13
324	Effects of Time to Treatment on Biochemical and Clinical Outcomes for Patients With Prostate Cancer Treated With Definitive Radiation. Clinical Genitourinary Cancer, 2016, 14, e463-e468.	1.9	0

#	ARTICLE	IF	CITATIONS
325	Editorial Comment. Urology, 2016, 87, 86-87.	1.0	0
326	The impact of Medicare eligibility on cancer screening behaviors. Preventive Medicine, 2016, 85, 47-52.	3.4	19
327	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Journal of Urology, 2016, 195, 399-405.	0.4	8
328	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	1.0	16
329	Causes of hospital readmissions after urologic cancer surgery. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 236.e1-236.e11.	1.6	36
330	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	7.1	94
331	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	7.1	86
332	A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities. BJU International, 2016, 117, 551-552.	2.5	31
333	Radical prostatectomy in metastatic prostate cancer: is there enough evidence? Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 880-882.	1.5	1
334	Understanding the roles of randomized trials for robotic prostatectomy. Annals of Translational Medicine, 2016, 4, 467-467.	1.7	1
335	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 54-54.	1.6	0
336	Open Versus Robotic Radical Prostatectomy in Obese Men. Current Urology, 2015, 8, 156-161.	0.6	12
337	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1351-1358.	4.9	17
338	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	4.9	37
339	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	4.9	72
340	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. Annals of Surgery, 2015, 262, 955-964.	4.2	101
341	An evaluation of the "weekend effect" in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	2.5	8
342	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU International, 2015, 116, 351-357.	2.5	29

#	ARTICLE	IF	CITATIONS
343	Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 525-530.	4.9	1
344	How can we improve surgical outcomes?. BJU International, 2015, 116, 835-836.	2.5	0
345	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU International, 2015, 116, 703-712.	2.5	11
346	Predictors of early continence following robot-assisted radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 93.	0.6	47
347	Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience. Canadian Urological Association Journal, 2015, 9, 434.	0.6	1
348	Factors predicting prolonged operative time for individual surgical steps of robot-assisted radical prostatectomy (RARP): A single surgeon's experience. Canadian Urological Association Journal, 2015, 9, 417.	0.6	16
349	NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. Canadian Urological Association Journal, 2015, 9, 164.	0.6	7
350	Impact of smoking on perioperative outcomes after major surgery. American Journal of Surgery, 2015, 210, 221-229.e6.	1.8	69
351	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	1.5	21
352	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	1.9	43
353	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. Urology, 2015, 85, 764-770.	1.0	18
354	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. Clinical Genitourinary Cancer, 2015, 13, e123-e130.	1.9	35
355	Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology, 2015, 86, 1165-1173.	1.0	8
356	Focal Therapy for Treatment of the Small Renal Mass: Dealer's Choice or a Therapeutic Gamble?. European Urology, 2015, 67, 260-261.	1.9	13
357	Reply. Urology, 2015, 85, 349-350.	1.0	0
358	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.4	32
359	Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU International, 2015, 115, 230-237.	2.5	18
360	Reply to Vincenzo Ficarra, Vito Palumbo, Afrovita Kungulli and Gianluca Giannarini's Letter to the Editor re: Andrea Minervini, Marco Carini, Robert G. Uzzo, Riccardo Campi, Marc C. Smaldone, Alexander Kutikov. Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score. Eur Urol 2014;66:803-5. European Urology, 2015, 67, e48-e51.	1.9	2

#	ARTICLE	IF	CITATIONS
361	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	1.0	21
362	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. <i>Journal of Urology</i> , 2015, 193, 820-825.	0.4	40
363	Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. <i>BJU International</i> , 2015, 116, 734-743.	2.5	35
364	Evidence from the â€”PROspective MulticEnTer Radical Cystectomy Series 2011 (PROMETRICS 2011)â€™ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1032-1042.	1.5	33
365	Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: Data from the nationwide emergency department sample, 2006 to 2011. <i>Journal of Pediatric Urology</i> , 2015, 11, 246.e1-246.e8.	1.1	44
366	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 142-149.	1.9	7
367	Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia Using the 180 Watt System: Multicenter Study of the Impact of Prostate Size on Safety and Outcomes. <i>Journal of Urology</i> , 2015, 194, 462-469.	0.4	50
368	Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate?. <i>European Urology</i> , 2015, 68, 1004-1006.	1.9	7
369	Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses. <i>Journal of Urology</i> , 2015, 194, 1548-1553.	0.4	59
370	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. <i>Journal of Endourology</i> , 2015, 29, 1052-1058.	2.1	23
371	Preventable mortality after common urological surgery: failing to rescue?. <i>BJU International</i> , 2015, 115, 666-674.	2.5	11
372	The need for standardised reporting of complications <sc>R</sc>: Minimum 5â€”years followâ€”up of 1138 consecutive laparoscopic radical prostatectomies. <i>BJU International</i> , 2015, 115, 501-502.	2.5	1
373	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 949-956.	1.9	50
374	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv054-djv054.	6.3	63
375	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. <i>Urology</i> , 2015, 85, 937-941.	1.0	21
376	Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e7-167.e12.	1.6	26
377	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). <i>American Journal of Cardiology</i> , 2015, 115, 1080-1084.	1.6	16
378	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. <i>World Journal of Urology</i> , 2015, 33, 2107-2113.	2.2	16

#	ARTICLE	IF	CITATIONS
379	Racial Disparities in Operative Outcomes After Major Cancer Surgery in the United States. World Journal of Surgery, 2015, 39, 634-643.	1.6	76
380	An evaluation of the timing of surgical complications following nephrectomy: data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). World Journal of Urology, 2015, 33, 2031-2038.	2.2	26
381	Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery. World Journal of Nephrology, 2015, 4, 160.	2.0	21
382	Incompletely Characterized Incidental Renal Masses: Emerging Data Support Conservative Management. Radiology, 2015, 275, 28-42.	7.3	98
383	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	1.9	57
384	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. World Journal of Surgery, 2015, 39, 2376-2385.	1.6	69
385	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	2.5	36
386	Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e19-388.e25.	1.6	36
387	Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. International Journal of Urology, 2015, 22, 89-95.	1.0	22
388	Complications After Surgery for Stress Urinary Incontinence. JAMA Surgery, 2015, 150, 1175.	4.3	2
389	Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy. Urology, 2015, 86, 300-306.	1.0	64
390	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	1.6	9
391	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.8	40
392	The influence of physician recommendation on prostate-specific antigen screening. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e1-424.e7.	1.6	28
393	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	1.6	21
394	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	7.4	105
395	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	2.5	66
396	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	1.6	24

#	ARTICLE	IF	CITATIONS
397	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	1.6	53
398	Sepsis after major cancer surgery. Journal of Surgical Research, 2015, 193, 788-794.	1.6	28
399	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. European Urology, 2015, 67, 3-6.	1.9	136
400	The Controversy That Will Not Go Away. European Urology, 2015, 67, 439-440.	1.9	3
401	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <scp>USA</scp>: a contemporary population-based analysis. BJU International, 2015, 115, 713-721.	2.5	79
402	Adjuvant cisplatin-based combined chemotherapy for lymph node (<scp>LN</scp>)â€positive urothelial carcinoma of the bladder (<scp>UCB</scp>) after radical cystectomy (<scp>RC</scp>): a retrospective international study of >1500 patients. BJU International, 2015, 115, 722-727.	2.5	22
403	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal, 2015, 9, 207.	0.6	13
404	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. Journal of Clinical Oncology, 2015, 33, 34-34.	1.6	0
405	Treatment of localized prostate cancer in elderly patients. Gland Surgery, 2015, 4, 283-7.	1.1	0
406	Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted". Annals of Translational Medicine, 2015, 3, 274.	1.7	1
407	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. Canadian Urological Association Journal, 2014, 8, 695.	0.6	42
408	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Canadian Urological Association Journal, 2014, 8, 681.	0.6	51
409	Utilization and perioperative outcomes of robotic vaginal vault suspension compared to abdominal or vaginal approaches for pelvic organ prolapse. Canadian Urological Association Journal, 2014, 8, 100.	0.6	12
410	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2014, 8, 148.	0.6	42
411	Urological resident exposure to transurethral surgical options for BPH management in 2012-2013: A pan-Canadian survey. Canadian Urological Association Journal, 2014, 8, 54.	0.6	8
412	Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU International, 2014, 113, 36-42.	2.5	37
413	Robotic and conventional open radical cystectomy lead to similar postoperative health-related quality of life. BJU International, 2014, 114, 793-794.	2.5	1
414	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.6	78

#	ARTICLE	IF	CITATIONS
415	Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. <i>BMJ Open</i> , 2014, 4, e003921.	1.9	36
416	Venous Thromboembolism After Major Cancer Surgery. <i>JAMA Surgery</i> , 2014, 149, 43.	4.3	158
417	Radical Cystectomy in the Elderly: National Trends and Disparities in Perioperative Outcomes and Quality of Care. <i>Urologia Internationalis</i> , 2014, 92, 27-34.	1.3	35
418	Engaging responsibly with social media: the <scp>BJU</scp> guidelines. <i>BJU International</i> , 2014, 114, 9-11.	2.5	74
419	Partial and radical nephrectomy provide comparable long-term cancer control for <scp>T</scp>1b renal cell carcinoma. <i>International Journal of Urology</i> , 2014, 21, 122-128.	1.0	32
420	Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. <i>BJU International</i> , 2014, 113, 200-208.	2.5	61
421	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. <i>BJU International</i> , 2014, 113, 733-740.	2.5	22
422	Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. <i>Cancer</i> , 2014, 120, 1532-1539.	4.1	204
423	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1259-1266.	1.6	50
424	Is a Minimally Invasive Approach the Solution for Reducing Surgical Site Infections?. <i>JAMA Surgery</i> , 2014, 149, 1044.	4.3	2
425	A Population-Based Assessment of the Burden of Acute Pancreatitis in the United States. <i>Pancreas</i> , 2014, 43, 687-691.	1.1	61
426	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. <i>JAMA Surgery</i> , 2014, 149, 1039.	4.3	109
427	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. <i>Journal of Clinical Oncology</i> , 2014, 32, 2025-2030.	1.6	112
428	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. <i>JAMA Internal Medicine</i> , 2014, 174, 1839.	5.1	33
429	Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population. <i>JAMA Internal Medicine</i> , 2014, 174, 1468.	5.1	1
430	The impact of resident involvement in minimally-invasive urologic oncology procedures. <i>Canadian Urological Association Journal</i> , 2014, 8, 334.	0.6	46
431	Delay in Nephrectomy and Cancer Control Outcomes in Elderly Patients with Small Renal Masses. <i>Urologia Internationalis</i> , 2014, 92, 455-461.	1.3	15
432	Emergency Department Visits in the United States for Upper Urinary Tract Stones: Trends in Hospitalization and Charges. <i>Journal of Urology</i> , 2014, 191, 90-96.	0.4	88

#	ARTICLE	IF	CITATIONS
433	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. <i>European Urology</i> , 2014, 66, 569-576.	1.9	205
434	Editorial Comment. <i>Urology</i> , 2014, 83, 779.	1.0	0
435	PD7-06 NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
436	Growth Kinetics and Short-Term Outcomes of cT1b and cT2 Renal Masses under Active Surveillance. <i>Journal of Urology</i> , 2014, 192, 659-664.	0.4	70
437	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	1.6	31
438	Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 1349-1354.	0.4	33
439	Local tumor destruction in renal cell carcinoma—An inpatient population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e1-54.e7.	1.6	10
440	Standardized assessment of complications in a contemporary series of <sc>E</sc>uropean patients undergoing radical cystectomy. <i>International Journal of Urology</i> , 2014, 21, 143-149.	1.0	106
441	The impact of androgen—deprivation therapy (<sc>ADT</sc>) on the risk of cardiovascular (<sc>CV</sc>) events in patients with non—metastatic prostate cancer: a population—based study. <i>BJU International</i> , 2014, 114, E82-E89.	2.5	77
442	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	1.9	134
443	Minimally Invasive vs Open Pyeloplasty in Children: The Differential Effect of Procedure Volume on Operative Outcomes. <i>Urology</i> , 2014, 84, 180-184.	1.0	24
444	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 1125-1132.	1.9	29
445	Renal Pelvic Anatomy Is Associated with Incidence, Grade, and Need for Intervention for Urine Leak Following Partial Nephrectomy. <i>European Urology</i> , 2014, 66, 949-955.	1.9	32
446	Correction of Ureteropelvic Junction Obstruction in Children: National Trends and Comparative Effectiveness in Operative Outcomes. <i>Journal of Endourology</i> , 2014, 28, 592-598.	2.1	46
447	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. <i>Journal of Urology</i> , 2014, 191, 764-770.	0.4	17
448	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. <i>European Urology</i> , 2014, 66, 561-568.	1.9	70
449	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing—risks analysis. <i>BJU International</i> , 2014, 114, E62-E69.	2.5	20
450	High hospital volume reduces mortality after cystectomy. <i>BJU International</i> , 2014, 114, 5-6.	2.5	1

#	ARTICLE	IF	CITATIONS
451	Use of advanced treatment technologies among men at low risk of dying from prostate cancer. BJU International, 2014, 114, 166-167.	2.5	1
452	Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends. Journal of Sexual Medicine, 2014, 11, 1063-1070.	0.6	39
453	Predicting Other-cause Mortality: The Minimalistic Approach. European Urology, 2014, 66, 1010-1011.	1.9	0
454	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. Urology, 2014, 84, 1152-1156.	1.0	12
455	Mental health outcomes in elderly men with prostate cancer1Equal contribution.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	1.6	59
456	Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surfaceâ€œIntermediateâ€œBase Margin Score. European Urology, 2014, 66, 803-805.	1.9	86
457	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	1.8	6
458	Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. Journal of Endourology, 2014, 28, 831-840.	2.1	64
459	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. Journal of Clinical Oncology, 2014, 32, 1419-1426.	1.6	169
460	Chronic kidney disease and perioperative outcomes in urological oncological surgery. International Journal of Urology, 2014, 21, 1245-1252.	1.0	14
461	Accuracy of Transrectal Ultrasonography to Evaluate Pathologic Prostate Weight: Correlation With Various Prostate Size Groups. Urology, 2014, 84, 169-174.	1.0	9
462	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	1.0	86
463	Internal Validation of the Renal Pelvic Score: A Novel Marker of Renal Pelvic Anatomy That Predicts Urine Leak After Partial Nephrectomy. Urology, 2014, 84, 351-357.	1.0	26
464	Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments. Journal of Endourology, 2014, 28, 784-791.	2.1	39
465	Predictors of admission in patients presenting to the emergency department with urinary tract infection. World Journal of Urology, 2014, 32, 813-819.	2.2	28
466	Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. World Journal of Urology, 2014, 32, 1511-1521.	2.2	14
467	Perioperative aspirin: To give or not to give?. BJU International, 2014, 114, 318-319.	2.5	0
468	Population-based determinants of radical prostatectomy operative time. BJU International, 2014, 113, E112-8.	2.5	22

#	ARTICLE	IF	CITATIONS
469	Association of type of renal surgery and access to robotic technology for kidney cancer: results from a population-based cohort. <i>BJU International</i> , 2014, 114, 549-554.	2.5	27
470	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. <i>Journal of Urology</i> , 2014, 191, 1678-1684.	0.4	19
471	Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e189-e195.	1.9	46
472	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. <i>Urology</i> , 2014, 83, 1316-1321.	1.0	17
473	Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. <i>European Urology</i> , 2014, 65, 235-241.	1.9	110
474	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 27.e7-27.e13.	1.6	24
475	PD12-12 ADJUVANT RADIOTHERAPY IMPROVES CANCER-SPECIFIC SURVIVAL ONLY IN PATIENTS WITH HIGHLY AGGRESSIVE PROSTATE CANCER. VALIDATION OF RECENTLY RELEASED CRITERIA. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
476	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. <i>European Urology</i> , 2014, 66, 666-672.	1.9	97
477	Practice Patterns and Outcomes of Open and Minimally Invasive Partial Nephrectomy Since the Introduction of Robotic Partial Nephrectomy: Results from the Nationwide Inpatient Sample. <i>Journal of Urology</i> , 2014, 191, 907-913.	0.4	197
478	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. <i>European Urology</i> , 2014, 66, 156-163.	1.9	156
479	Editorial Comment. <i>Urology</i> , 2014, 83, 630-631.	1.0	0
480	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 46.e1-46.e7.	1.6	25
481	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 352-358.	1.0	21
482	Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 277-283.	0.8	3
483	Patients with anatomically "simple" renal masses are more likely to be placed on active surveillance than those with anatomically "complex" lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1267-1271.	1.6	13
484	Anatomic Complexity Quantitated by Nephrometry Score Is Associated With Prolonged Warm Ischemia Time During Robotic Partial Nephrectomy. <i>Urology</i> , 2014, 84, 340-344.	1.0	27
485	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1285-1291.	1.6	81
486	Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption. <i>Urology</i> , 2014, 83, 1285-1293.	1.0	26

#	ARTICLE	IF	CITATIONS
487	Assessing the Burden of Complications After Surgery for Clinically Localized Kidney Cancer by Age and Comorbidity Status. <i>Urology</i> , 2014, 83, 843-850.	1.0	63
488	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	1.9	201
489	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 29.e13-29.e20.	1.6	34
490	Heterogeneity and renal mass biopsy: a review of its role and reliability. <i>Cancer Biology and Medicine</i> , 2014, 11, 162-72.	3.0	69
491	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5091-5091.	1.6	0
492	Readmissions after major urologic cancer surgery. <i>Canadian Journal of Urology</i> , 2014, 21, 7537-46.	0.0	24
493	Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. <i>BJU International</i> , 2013, 111, 67-73.	2.5	54
494	Conditional survival after nephrectomy for renal cell carcinoma (<sc>RCC</sc>): changes in future survival probability over time. <i>BJU International</i> , 2013, 111, E283-9.	2.5	33
495	Sociodemographic disparities in the treatment of small renal masses. <i>BJU International</i> , 2013, 111, E274-82.	2.5	23
496	Health care-associated infections after major cancer surgery. <i>Cancer</i> , 2013, 119, 2317-2324.	4.1	24
497	In-hospital mortality and failure-to-rescue rates after radical cystectomy. <i>BJU International</i> , 2013, 112, E20-7.	2.5	28
498	Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. <i>BJU International</i> , 2013, 112, E273-80.	2.5	31
499	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.4	40
500	1635 BENEFIT IN REGIONALIZATION OF CARE FOR PATIENTS TREATED WITH NEPHRECTOMY: A NATIONWIDE INPATIENT SAMPLE. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
501	180 W vs 120 W Lithium Triborate Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia: A Global, Multicenter Comparative Analysis of Perioperative Treatment Parameters. <i>Urology</i> , 2013, 82, 1108-1113.	1.0	44
502	Balancing Process and Risk: Standardizing Posttreatment Surveillance for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 417-418.	0.4	13
503	Oncological vs functional outcomes for RARP—finding a balance. <i>Nature Reviews Urology</i> , 2013, 10, 563-564.	3.8	0
504	Re: Surgeon Variation in Patient Quality of Life after Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 190, 1441-1442.	0.4	0

#	ARTICLE	IF	CITATIONS
505	Reply from Authors re: Brian R. Matlaga. How Do We Manage Infected, Obstructed Hydronephrosis? Eur Urol 2013;64:93â€“4. European Urology, 2013, 64, 95-96.	1.9	1
506	Active surveillance of small renal masses. Nature Reviews Urology, 2013, 10, 266-274.	3.8	37
507	Robot-Assisted Versus Open Radical Prostatectomy: The Differential Effect of Regionalization, Procedure Volume and Operative Approach. Journal of Urology, 2013, 189, 1289-1294.	0.4	81
508	Radiation Safety Knowledge and Practices Among Urology Residents and Fellows: Results of a Nationwide Survey. Journal of Surgical Education, 2013, 70, 224-231.	2.5	61
509	Effect of Nodal Metastases on Cancer-specific Mortality After Cyto-reductive Nephrectomy. Annals of Surgical Oncology, 2013, 20, 2096-2102.	1.5	18
510	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	1.9	47
511	Robotic ultrasound probe for tumor identification in robotic partial nephrectomy: Initial series and outcomes. International Journal of Urology, 2013, 20, 172-176.	1.0	71
512	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
513	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 5-11.	2.2	39
514	52 TOTAL AND PARTIAL ADRENALECTOMY HAVE SIMILAR PERI-OPERATIVE OUTCOMES. Journal of Urology, 2013, 189, .	0.4	0
515	Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumasâ€™ Letter to the Editor re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. Eur Urol 2012;62:696â€“703. European Urology, 2013, 63, e65-e66.	1.9	0
516	Clinical Characteristics Associated With Treatment Type for Localized Renal Tumors: Implications for Practice Pattern Assessment. Urology, 2013, 81, 269-276.	1.0	26
517	Incidence of Priapism in Emergency Departments in the United States. Journal of Urology, 2013, 190, 1275-1280.	0.4	75
518	Effect of metabolic syndrome on pathologic features of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1054-1059.	1.6	44
519	Off-clamp Robot-assisted Partial Nephrectomy Preserves Renal Function: A Multi-institutional Propensity Score Analysis. European Urology, 2013, 64, 988-993.	1.9	101
520	Disparities in Access to Hospitals with Robotic Surgery for Patients with Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2013, 189, 514-520.	0.4	57
521	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1663-1669.	1.6	38
522	Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States. Journal of Urology, 2013, 190, 1798-1804.	0.4	15

#	ARTICLE	IF	CITATIONS
523	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	1.9	101
524	Discharge patterns after radical prostatectomy in the United States of America. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1022-1032.	1.6	22
525	1634 MANAGEMENT OF LOCALIZED KIDNEY CANCER: CALCULATING CANCER-SPECIFIC MORTALITY AND COMPETING-RISKS OF DEATH TRADEOFFS BETWEEN SURGERY AND ACTIVE SURVEILLANCE. <i>Journal of Urology</i> , 2013, 189, .	0.4	3
526	Trends in Percutaneous Nephrolithotomy Use and Outcomes in the United States. <i>Journal of Urology</i> , 2013, 190, 558-564.	0.4	80
527	1701 ACCURACY OF THE EORTC RISK TABLES AND OF THE CUETO SCORING MODEL TO PREDICT OUTCOMES IN NON MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2013, 189, .	0.4	2
528	Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: A detailed assessment of margin extent and location. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1470-1476.	1.6	24
529	A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology</i> , 2013, 64, 786-798.	1.9	172
530	Clinical Implementation of Quality of Life Instruments and Prediction Tools for Localized Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>Journal of Urology</i> , 2013, 189, 2092-2098.	0.4	42
531	Re: Perioperative Outcomes and Oncologic Efficacy from a Pilot Prospective Randomized Clinical Trial of Open Versus Robotic Assisted Radical Cystectomy. <i>Journal of Urology</i> , 2013, 190, 811-812.	0.4	1
532	In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. <i>European Urology</i> , 2013, 63, 1107-1114.	1.9	51
533	Reply to Hiten D. Patel and Mohamad E. Allaf's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034 . <i>European Urology</i> , 2013, 64, e107-e108.	1.9	2
534	Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (<scp>NMIBC</scp>) from a single centre. <i>BJU International</i> , 2013, 111, E331-41.	2.5	18
535	Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. <i>International Journal of Urology</i> , 2013, 20, 372-380.	1.0	22
536	Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. <i>BJU International</i> , 2013, 111, 1208-1214.	2.5	35
537	Temporal Trends, Practice Patterns, and Treatment Outcomes for Infected Upper Urinary Tract Stones in the United States. <i>European Urology</i> , 2013, 64, 85-92.	1.9	71
538	Hospitalization Costs for Radical Prostatectomy Attributable to Robotic Surgery. <i>European Urology</i> , 2013, 64, 11-16.	1.9	44
539	National trends in hospital-acquired preventable adverse events after major cancer surgery in the USA. <i>BMJ Open</i> , 2013, 3, e002843.	1.9	32
540	FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients. <i>Modern Pathology</i> , 2013, 26, 1144-1149.	5.5	10

#	ARTICLE	IF	CITATIONS
541	Statistical Analysis Plans in Observational Research. JAMA - Journal of the American Medical Association, 2013, 309, 32.	7.4	3
542	Prostate Cancer Screening and Incidence: A Question of Causality. JAMA Internal Medicine, 2013, 173, 392.	5.1	0
543	Rates of open versus laparoscopic and partial versus radical nephrectomy for <scp>T</scp>1a renal cell carcinoma: A populationâ€based evaluation. International Journal of Urology, 2013, 20, 1064-1071.	1.0	35
544	Contemporary Volumeâ€Outcome Relationships for Percutaneous Nephrolithotomy: Results from the Nationwide Inpatient Sample. Journal of Endourology, 2013, 27, 1107-1113.	2.1	22
545	Predictors of Immediate Continence Following Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2013, 27, 442-446.	2.1	47
546	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	2.5	31
547	Percutaneous suprapubic tube bladder drainage after robot-assisted radical prostatectomy: a step-by-step guide. BJU International, 2013, 112, 703-705.	2.5	10
548	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	2.5	128
549	Trends in surgery for upper urinary tract calculi in the <scp>USA</scp> using the <scp>N</scp>ationwide <scp>I</scp>npatient <scp>S</scp>ample: 1999â€2009. BJU International, 2013, 112, 224-230.	2.5	65
550	The Kubler-Ross model, physician distress, and performance reporting. Nature Reviews Urology, 2013, 10, 425-428.	3.8	7
551	Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 377-386.	1.5	24
552	Disparities in Outcomes following Admission for Cholangitis. PLoS ONE, 2013, 8, e59487.	2.5	9
553	Concerning Trends in the Management of Metastatic Pancreatic Cancer. American Journal of Gastroenterology, 2013, 108, S89.	0.4	0
554	Adoption of Robotic Surgery: An Analogy From Urologic Oncology. Journal of Clinical Oncology, 2012, 30, 2931-2932.	1.6	4
555	Is robotic surgery cost-effective. Current Opinion in Urology, 2012, 22, 61-65.	1.8	48
556	Objectifying risk for localized renal masses. Nature Reviews Urology, 2012, 9, 70-72.	3.8	2
557	Vattikuti Institute Prostatectomyâ€Technique in 2012. Journal of Endourology, 2012, 26, 1558-1565.	2.1	36
558	Are Medicare-Based Findings Applicable to All Prostatectomy Patients?. Journal of Clinical Oncology, 2012, 30, 2286-2287.	1.6	4

#	ARTICLE	IF	CITATIONS
559	Proof of Efficacy Is Not Enough: Contemporary Management of Patients With Metastatic Renal Cell Carcinoma With Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 3901-3901.	1.6	3
560	Variations in the quality of care at radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012, 4, 61-75.	2.0	5
561	Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 395.	3.2	14
562	Venous Thromboembolism in Colorectal Surgery: How Much Does Laparoscopy Impart an Advantage?. <i>Archives of Surgery</i> , 2012, 147, 199.	2.2	1
563	Training and outcome monitoring in robotic urologic surgery. <i>Nature Reviews Urology</i> , 2012, 9, 17-22.	3.8	10
564	Editorial Comment to Robotâ€‘assisted or pure laparoscopic nerveâ€‘sparing radical prostatectomy: What is the optimal procedure for the surgical margins? A single center experience. <i>International Journal of Urology</i> , 2012, 19, 1082-1082.	1.0	0
565	THE CASE FOR PARTIAL NEPHRECTOMY: ACTION IS REQUIRED. <i>BJU International</i> , 2012, 110, 1097-1098.	2.5	1
566	Does partial nephrectomy at an academic institution result in better outcomes?. <i>World Journal of Urology</i> , 2012, 30, 505-510.	2.2	7
567	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	2.2	16
568	Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. <i>European Urology</i> , 2012, 62, 696-703.	1.9	129
569	Reply to Gurdarshan S. Sandhu, Youssef S. Tanagho and Sam B. Bhayani's Letter to the Editor re: Maxine Sun, Quoc-Dien Trinh, Marco Bianchi, et al. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. <i>Eur Urol</i> . 2012;61:725â€‘31. <i>European Urology</i> , 2012, 62, e59-e60.	1.9	0
570	Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. <i>Journal of Urology</i> , 2012, 187, 405-410.	0.4	58
571	Discharge Patterns After Radical Cystectomy: Contemporary Trends in the United States. <i>Journal of Urology</i> , 2012, 187, 1206-1209.	0.4	4
572	Re: Improved Prediction of Long-Term, Other Cause Mortality in Men With Prostate Cancer. <i>Journal of Urology</i> , 2012, 187, 1931-1931.	0.4	0
573	Re: A Double-Blind Randomized Controlled Clinical Trial to Assess the Effect of Doppler Optimized Intraoperative Fluid Management on Outcome Following Radical Cystectomy. <i>Journal of Urology</i> , 2012, 187, 2278-2279.	0.4	0
574	358 CREATION OF A PREOPERATIVE NOMOGRAM THAT INCLUDES ENDORECTAL MRI ACCURATELY PREDICTS NON ORGAN-CONFINED PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
575	V405 ENUCLEATION TECHNIQUES FOR CHALLENGING ROBOT-ASSISTED PARTIAL NEPHRECTOMY CASES. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
576	Tablet Telerounding. <i>Urology</i> , 2012, 80, 1383-1388.	1.0	25

#	ARTICLE	IF	CITATIONS
577	1390 PROSPECTIVE, RANDOMIZED USE OF THE VLOC VESICourethRAL ANASTAMOSIS DURING ROBOT ASSISTED RADICAL PROSTATECTOMY: LONG-TERM FOLLOWUP. Journal of Urology, 2012, 187, .	0.4	0
578	Tu1715 Biliary Drainage Method and Temporal Trends in Patients Admitted With Cholangitis: A National Audit. Gastrointestinal Endoscopy, 2012, 75, AB498.	1.0	0
579	1466 PREOPERATIVE NOMOGRAM PREDICTING ERECTILE FUNCTION TWO YEARS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.4	3
580	Blood Transfusions in Radical Prostatectomy: A Contemporary Population-based Analysis. Urology, 2012, 79, 332-338.	1.0	18
581	Annual Prostatectomy Volume Is Related to Rectal Laceration Rate After Radical Prostatectomy. Urology, 2012, 79, 796-803.	1.0	12
582	Assessing Performance Trends in Laparoscopic Nephrectomy and Nephron-sparing Surgery for Localized Renal Tumors. Urology, 2012, 80, 286-292.	1.0	53
583	Robot-assisted urological surgery: Current status and future perspectives. Arab Journal of Urology Arab Association of Urology, 2012, 10, 17-22.	1.5	5
584	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. European Journal of Cancer, 2012, 48, 1503-1511.	2.8	50
585	Conditional survival of patients with metastatic renal-cell carcinoma. Lancet Oncology, The, 2012, 13, e462.	10.7	11
586	Causality in administrative datasets. Journal of Crohn's and Colitis, 2012, 6, 867.	1.3	1
587	Re: Complications after Prostate Biopsy: Data from SEER-Medicare. Journal of Urology, 2012, 188, 677-678.	0.4	1
588	National Trends and Disparities in the Use of Minimally Invasive Adult Pyeloplasty. Journal of Urology, 2012, 188, 913-918.	0.4	44
589	1597 GENDER DIFFERENCES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY A POPULATION-BASED ANALYSIS. Journal of Urology, 2012, 187, .	0.4	3
590	V1027 ROBOT-ASSISTED SIMPLE PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.4	0
591	Does Partial Nephrectomy Result in a Durable Overall Survival Benefit in the Medicare Population?. Journal of Urology, 2012, 188, 2089-2094.	0.4	46
592	Morbidity and mortality of radical prostatectomy differs by insurance status. Cancer, 2012, 118, 1803-1810.	4.1	41
593	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. Cancer, 2012, 118, 1894-1900.	4.1	25
594	Disparities in access to care at high-volume institutions for urologic oncologic procedures. Cancer, 2012, 118, 4421-4426.	4.1	65

#	ARTICLE	IF	CITATIONS
595	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. Cancer, 2012, 118, 4991-4998.	4.1	17
596	The effect of insurance status on outcomes after partial nephrectomy. International Urology and Nephrology, 2012, 44, 343-351.	1.4	11
597	The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. International Urology and Nephrology, 2012, 44, 799-806.	1.4	7
598	THE PHANTOM MENACE OF PROSTATE CANCER SCREENING. BJU International, 2012, 109, 324-326.	2.5	0
599	A Nonâ€“Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. European Urology, 2012, 61, 725-731.	1.9	124
600	Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. European Urology, 2012, 61, 715-721.	1.9	65
601	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. European Urology, 2012, 61, 679-685.	1.9	345
602	Robot-assisted Radical Prostatectomy: Ready To Be Counted?. European Urology, 2012, 62, 16-18.	1.9	6
603	A Review of Integrated Staging Systems for Renal Cell Carcinoma. European Urology, 2012, 62, 303-314.	1.9	108
604	Is a Treatment Delay in Radical Prostatectomy Safe in Individuals with Lowâ€“Risk Prostate Cancer?. Journal of Sexual Medicine, 2012, 9, 2961-2969.	0.6	31
605	Open radical prostatectomy in the elderly: a case for concern?. BJU International, 2012, 109, 1335-1340.	2.5	14
606	Nodeâ€“positive renal cell carcinoma in the absence of distant metastases: predictors of cancerâ€“specific mortality in a populationâ€“based cohort. BJU International, 2012, 110, E21-7.	2.5	28
607	Prospective randomized trial of barbed polyglyconate suture to facilitate vesicoâ€“urethral anastomosis during robotâ€“assisted radical prostatectomy: time reduction and cost benefit. BJU International, 2012, 109, 1526-1532.	2.5	65
608	Longâ€“term followâ€“up of patients undergoing percutaneous suprapubic tube drainage after robotâ€“assisted radical prostatectomy (RARP). BJU International, 2012, 110, 580-585.	2.5	38
609	Higher perioperative morbidity and inâ€“hospital mortality in patients with endâ€“stage renal disease undergoing nephrectomy for nonâ€“metastatic kidney cancer: a populationâ€“based analysis. BJU International, 2012, 110, E183-90.	2.5	19
610	Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. BJU International, 2012, 110, 828-833.	2.5	15
611	Marital status: a genderâ€“independent risk factor for poorer survival after radical cystectomy. BJU International, 2012, 110, 1301-1309.	2.5	53
612	Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. Annals of Surgical Oncology, 2012, 19, 2380-2387.	1.5	91

#	ARTICLE	IF	CITATIONS
613	Small renal masses progressing to metastases under active surveillance. <i>Cancer</i> , 2012, 118, 997-1006.	4.1	332
614	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. <i>Canadian Urological Association Journal</i> , 2012, 6, 245-250.	0.6	16
615	The effect of gender on nephrectomy perioperative outcomes: a national survey. <i>Canadian Journal of Urology</i> , 2012, 19, 6337-44.	0.0	5
616	V1882 ROBOT ASSISTED PROSTATE-SPARING RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.4	0
617	Adjuvant and Neoadjuvant Therapies in High-Risk Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 765-791.	2.2	27
618	Anastomosis During Robot-assisted Radical Prostatectomy: Randomized Controlled Trial Comparing Barbed and Standard Monofilament Suture. <i>Urology</i> , 2011, 78, 572-579.	1.0	56
619	Oncological and Functional Outcomes After Robot-assisted Radical Cystectomy: Critical Review of Current Status. <i>Urology</i> , 2011, 78, 977-984.	1.0	26
620	Molecular imaging of the small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 589-592.	1.6	4
621	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. <i>Journal of Urology</i> , 2011, 186, 1849-1854.	0.4	33
622	Editorial Comment. <i>Journal of Urology</i> , 2011, 186, 1777-1778.	0.4	2
623	Robotic radical prostatectomy: a critical analysis of surgical quality. <i>Current Opinion in Urology</i> , 2011, 21, 195-199.	1.8	8
624	Safety Profile of Robot-Assisted Radical Prostatectomy: A Standardized Report of Complications in 3317 Patients. <i>European Urology</i> , 2011, 59, 684-698.	1.9	114
625	A Population-Based Analysis of Temporal Perioperative Complication Rates After Minimally Invasive Radical Prostatectomy. <i>European Urology</i> , 2011, 60, 564-571.	1.9	20
626	A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis. <i>European Urology</i> , 2011, 60, 1152-1159.	1.9	43
627	Active surveillance: a potential strategy for select patients with small renal masses. <i>Future Oncology</i> , 2011, 7, 1133-1147.	2.4	12
628	Surgery for high-risk localized prostate cancer. <i>Therapeutic Advances in Urology</i> , 2011, 3, 173-182.	2.0	13
629	Novel method of knotless vesicourethral anastomosis during robot-assisted radical prostatectomy: feasibility study and early outcomes in 30 patients using the interlocked barbed unidirectional V-LOC180 suture. <i>Canadian Urological Association Journal</i> , 2011, 5, 188-194.	0.6	33
630	Robot-Assisted Partial Nephrectomy. <i>Videourology (New Rochelle, N Y)</i> , 2011, 25, .	0.1	0

#	ARTICLE	IF	CITATIONS
631	BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 607-16.	2.8	71
632	The current management of small renal masses. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 180-185.	1.3	4
633	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2008, 123, 395-400.	5.1	159
634	Editorial Comment on: A Novel Approach to Energy Ablative Therapy of Small Renal Tumours: Laparoscopic High-Intensity Focused Ultrasound. <i>European Urology</i> , 2008, 53, 817-818.	1.9	2
635	Development of a Highly Accurate Nomogram for Prediction of the Need for Exploration in Patients With Renal Trauma. <i>Journal of Trauma</i> , 2008, 64, 1451-1458.	2.3	38
636	Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram. <i>Journal of Clinical Oncology</i> , 2007, 25, 1316-1322.	1.6	470
637	ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. <i>European Journal of Cancer</i> , 2007, 43, 1023-1029.	2.8	25
638	Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. <i>Journal of Urology</i> , 2007, 178, 1229-1237.	0.4	22
639	Prognostic ability of simplified nuclear grading of renal cell carcinoma. <i>Cancer</i> , 2007, 109, 868-874.	4.1	115
640	C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. <i>Cancer</i> , 2007, 110, 1241-1247.	4.1	165
641	Clinicians are poor raters of life expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. <i>BJU International</i> , 2007, 100, 1254-1258.	2.5	129
642	Unclassified renal cell carcinoma: an analysis of 85 cases. <i>BJU International</i> , 2007, 100, 802-808.	2.5	38
643	Sunitinib Relieves Renal Cell Carcinoma Spinal Cord Compression. <i>European Urology</i> , 2007, 51, 1741-1743.	1.9	10
644	Sutent Relieves Renal Cell Carcinoma Spinal Cord Compression: Part II. <i>European Urology</i> , 2007, 52, 273-274.	1.9	0
645	Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. <i>European Urology</i> , 2007, 51, 1616-1624.	1.9	93
646	Collecting Duct Renal Cell Carcinoma: A Matched Analysis of 41 Cases. <i>European Urology</i> , 2007, 52, 1140-1146.	1.9	88
647	Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality. <i>European Urology</i> , 2007, 52, 1428-1437.	1.9	30
648	1245: The Presence of Tumor Necrosis within the Primary Tumor Cannot Independently Predict Renal Cell Carcinoma-Specific Mortality after Nephrectomy. <i>Journal of Urology</i> , 2007, 177, 410-410.	0.4	3

#	ARTICLE	IF	CITATIONS
649	1246: Nephron-Sparing Surgery does not Undermine Renal Cell Carcinoma-Specific Survival in Patients with PT3 Renal Cell Carcinoma. Journal of Urology, 2007, 177, 411-411.	0.4	2
650	1427: Circulating Levels of Plasminogen Activation Inhibitor-1 Improve the Accuracy of Pre- and Post-Operative Nomograms for Prediction of Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2007, 177, 471-471.	0.4	0
651	Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Human Molecular Genetics, 2003, 12, 2967-2979.	2.9	103
652	The Medical Necessity of Nephron-Sparing Surgery. International Journal of Clinical Reviews, 0, , .	0.1	0
653	Oncological Outcomes of cT1 and cT2 Micropapillary Variant Compared With cT1 and cT2 Conventional Urothelial Carcinoma Treated With Radical Cystectomy. Urology Practice, 0, , .	0.5	0